Redeye saw a Q3 report that was both better and weaker than expected. Sales beat expectations paired with higher costs, producing lower results than expected. The German market continues to shine while we await a real breakthrough in the US due to the slow reimbursement process. We have adjusted our estimates for 2024/25e due to the slower US development and added an equity issue in our model. The dilutive effect is the primary reason for the lowered Based case to SEK 4.3(6.8) per share.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Scibase - Increased focus on sales development

© Modular Finance, source Nordic Press Releases